Program Description
Activation of the Janus-associated kinase (JAK)/signal transducers and activators of the transcription pathway has been shown to play a crucial role in disease development and progression of myelofibrosis (MF). JAK inhibitors have emerged as guideline-recommended treatment options for patients with MF who are not eligible for allogeneic stem cell transplantation, yet nearly half of patients experience treatment failure. Oncology pharmacists must be prepared to navigate the management of adverse effects, considerations for dose tapering or switching, and other clinical challenges associated with JAK inhibitor treatment failure to prevent treatment discontinuation. Along with clinical efficacy and real-world data, this program will additionally review best practices for oncology pharmacists in the provision of supportive care to optimize management of JAK inhibitors in patients with MF.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: November 16, 2023
Expiration date: January 16, 2024
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply clinical evidence to the selection of Janus-associated kinase (JAK) inhibitors in the management of myelofibrosis
- Ensure timely interventions after JAK inhibitor failure to mitigate disease progression
- Construct comprehensive care plans for patients with myelofibrosis, incorporating supportive care interventions, symptom management strategies, and appropriate monitoring for adverse effects.
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-389-L01-P. The activity is available for CE credit through January 16, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Victoria Nachar, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: BeiGene
Advisor: Genmab, ADC Therapeutics
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.[CT1]
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms